Biotech

All Articles

Acelyrin loses izokibep, lays off 3rd of team

.Even with izokibep keeping its own newly found winning streak in the clinic, Acelyrin is actually n...

Rivus' period 2 obesity-related heart failure trial hits endpoint

.Rivus Pharmaceuticals has plumped up the leads of its own fat-busting, muscle-sparing medication ca...

Ovid halts preclinical work, IV system after soticlestat fail

.Ovid Rehab currently disclosed last month that it was trimming its headcount as the company gets th...

Eli Lilly opens up $700M nucleic acid R&ampD facility in Boston ma Seaport

.Eli Lilly has opened up a $700 thousand R&ampD facility in the Boston ma Port, enhancing its RNA an...

Boundless Bio helps make 'moderate' layoffs five months after $100M IPO

.Just five months after protecting a $one hundred million IPO, Vast Bio is already laying off some e...

Halda's $126M is going to accelerate 'secure and eliminate' cyst drugs

.The first phases of oncology R&ampD aren't except fascinating brand-new modalities, and Halda Rehab...

Lykos 'disappointments' not divulging research study infractions with publisher

.Psychopharmacology has pulled 3 write-ups about midstage professional test data analyzing Lykos Reh...

Analysts examine Avidity's DMD succeed, showing distinctions in information

.Avidity Biosciences amazed entrepreneurs along with period 1/2 data in Duchenne muscle dystrophy (D...

Actinogen's cortisol blocker neglects period 2 clinical depression study

.Actinogen Medical's cortisol blocker has missed out on the primary endpoint of a stage 2 study in d...

Bivictrix chooses going personal only way to take ADC in to clinic

.Antibody-drug conjugates (ADCs) have actually gone to the center of numerous a billion-dollar biobu...